Theravance signs cardiovascular drug development deal with Merck

Merck & Co. and Theravance agreed to develop the latter's small molecule therapeutic candidates for hypertension and heart failure. The agreement grants Merck exclusive, worldwide rights to Theravance's drug candidates. Theravance will receive $5 million upfront and as much as $148 million in milestone fees for the initial indication plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News · Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA